NASDAQ:BPTS

Biophytis (BPTS) Stock Forecast, Price & News

$1.24

-0.06 (-4.62%)

(As of 09/29/2023 08:52 PM ET)

Compare

Today's Range: $1.19
▼
$1.29
50-Day Range: $0.92
▼
$2.06
52-Week Range: $0.88
▼
$9.02

Volume: 98,600 shs
Average Volume: 561,130 shs
Market Capitalization: $8.48 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

Biophytis MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,109.7% Upside
$15.00 Price Target
Short Interest: Healthy
0.97% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.67
Based on 10 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.09) to ($0.06) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Biophytis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.00, Biophytis has a forecasted upside of 1,109.7% from its current price of $1.24.
Amount of Analyst Coverage
Biophytis has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.97% of the outstanding shares of Biophytis have been sold short.
Short Interest Ratio / Days to Cover
Biophytis has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Biophytis has recently decreased by 3.63%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Biophytis does not currently pay a dividend.
Dividend Growth
Biophytis does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BPTS.

3.1

News and Social Media Coverage

News Sentiment
Biophytis has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Biophytis this week, compared to 1 article on an average week.
Search Interest
2 people have searched for BPTS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
1 people have added Biophytis to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biophytis insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.70% of the stock of Biophytis is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Biophytis are expected to grow in the coming year, from ($0.09) to ($0.06) per share.

See Top Rated MarketRank™ Stocks Here

About Biophytis (NASDAQ:BPTS) Stock

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

BPTS Price History

30 days | 90 days | 365 days | Advanced Chart

BPTS Stock News Headlines

September 29, 2023 | proactiveinvestors.com

Biophytis shares surge 41% following Covid partnership with France's Skyepharma

September 26, 2023 | finance.yahoo.com

Biophytis (BPTS) Soars 73% on Partnership With Skyepharma

October 2, 2023 | Wall Street Fundamentals (Ad)

How is This "Hidden Gem" Thriving in a Turbulent Market?

While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.

September 25, 2023 | benzinga.com

Why Biophytis (BPTS) Shares Are Sky-Rocketing

September 25, 2023 | markets.businessinsider.com

Biophytis Shares Surge 79% Following Covid-19 Partnership With Skyepharma

September 25, 2023 | marketwatch.com

Biophytis Shares Rise 41% After Partnership Deal With Skyepharma

September 25, 2023 | finance.yahoo.com

Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)

September 25, 2023 | msn.com

Why Is Biophytis (BPTS) Stock Up 49% Today?

October 2, 2023 | Wall Street Fundamentals (Ad)

How is This "Hidden Gem" Thriving in a Turbulent Market?

September 25, 2023 | finance.yahoo.com

Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)

September 20, 2023 | finanznachrichten.de

Biophytis Provides an Update on its Early Access Programs for Sarconeos in the Treatment of Severe Forms of COVID-19

September 19, 2023 | finance.yahoo.com

Biophytis Provides an Update on its Early Access Programs for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19

September 14, 2023 | finance.yahoo.com

Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer

September 11, 2023 | finanznachrichten.de

Biophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in Sarcopenia

September 11, 2023 | finance.yahoo.com

Biophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in Sarcopenia

September 4, 2023 | finance.yahoo.com

Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New York

August 16, 2023 | finance.yahoo.com

Biophytis Announces Next Regulatory Steps in Europe and the United States for its COVA Project

August 8, 2023 | msn.com

Why Is Biophytis (BPTS) Stock Up 18% Today?

August 8, 2023 | finance.yahoo.com

Biophytis Receives a Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe

July 20, 2023 | marketwatch.com

Biophytis Shares Drop 11% After Request for Meeting With FDA on Covid-19 Treatment

July 20, 2023 | finance.yahoo.com

Biophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19

July 20, 2023 | finance.yahoo.com

Biophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19

July 19, 2023 | marketwatch.com

Biophytis Shares Drop 12% on Direct Offering Pricing

July 19, 2023 | finanznachrichten.de

Biophytis Announces USD3.8 Million Registered Direct Offering

July 19, 2023 | finance.yahoo.com

Biophytis Announces $3.8 Million Registered Direct Offering

July 18, 2023 | seekingalpha.com

iCAD, Biophytis top healthcare gainers; Lixte, Masimo lead losers pack

July 18, 2023 | benzinga.com

Why Are Biophytis Shares Skyrocketing Today?

See More Headlines

Receive BPTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biophytis and its competitors with MarketBeat's FREE daily newsletter.

BPTS Company Calendar

Today: 10/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BPTS
CUSIP: N/A
CIK: 1768946
Web: www.biophytis.com
Phone: 33-1-44-37-23-00
Fax: N/A
Employees: 24
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $15.00
High Stock Price Forecast: $15.00
Low Stock Price Forecast: $15.00
Forecasted Upside/Downside: +1,109.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.81
Quick Ratio: 0.96

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.84) per share
Price / Book: -1.48

Miscellaneous

Outstanding Shares: 5,100,000
Free Float: 4,910,000
Market Cap: $6.32 million
Optionable: Not Optionable
Beta: 1.03

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Stanislas Veillet Ph.D. (Age 58)
Chairman & CEO
Comp: $456.76k

Mr. Nicolas Fellmann (Age 55)
Chief Financial Officer

Mr. Waly Dioh Ph.D. (Age 54)
Chief Clinical Operating Officer

Dr. Pierre J. Dilda (Age 53)
Chief Scientific Officer

Dr. Rene Lafont (Age 77)
Scientific Advisor & Member of Scientific Advisory Board

Dr. Rob van Maanen FFPM (Age 53)
M.B.A., M.D., Chief Medical Officer

Ms. _ Teylan
Financial Controller

Key Competitors

View All Competitors

BPTS Stock - Frequently Asked Questions

Should I buy or sell Biophytis stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biophytis in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BPTS shares.
View BPTS analyst ratings or view top-rated stocks.
What is Biophytis' stock price forecast for 2023?: 1 brokerages have issued 1 year price objectives for Biophytis' stock. Their BPTS share price forecasts range from $15.00 to $15.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 1,109.7% from the stock's current price.
View analysts price targets for BPTS or view top-rated stocks among Wall Street analysts.
How have BPTS shares performed in 2023?: Biophytis' stock was trading at $3.9510 at the start of the year. Since then, BPTS stock has decreased by 68.6% and is now trading at $1.24.
View the best growth stocks for 2023 here.
When did Biophytis' stock split?: Shares of Biophytis reverse split on Thursday, March 30th 2023. The 1-10 reverse split was announced on Thursday, March 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Biophytis IPO?: (BPTS) raised $20 million in an IPO on Wednesday, February 10th 2021. The company issued 1,200,000 shares at $15.00-$18.00 per share. H.C. Wainwright acted as the underwriter for the IPO.
What is Biophytis' stock symbol?: Biophytis trades on the NASDAQ under the ticker symbol "BPTS."
How do I buy shares of Biophytis?: Shares of BPTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Biophytis' stock price today?: One share of BPTS stock can currently be purchased for approximately $1.24.
How much money does Biophytis make?: Biophytis (NASDAQ:BPTS) has a market capitalization of $6.32 million.
How can I contact Biophytis?: Biophytis' mailing address is SORBONNE UNIVERSITY BC 9 BATIMENT A 4EME ETAGE 4 PLACE JUSSIEU, PARIS I0, 75252. The official website for the company is www.biophytis.com. The company can be reached via phone at 33-1-44-37-23-00.

This page (NASDAQ:BPTS) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial